2024
Recent Advances in the Treatment of Treatment-Resistant Depression: A Narrative Review of Literature Published from 2018 to 2023
Havlik J, Wahid S, Teopiz K, McIntyre R, Krystal J, Rhee T. Recent Advances in the Treatment of Treatment-Resistant Depression: A Narrative Review of Literature Published from 2018 to 2023. Current Psychiatry Reports 2024, 26: 176-213. PMID: 38386251, DOI: 10.1007/s11920-024-01494-4.Peer-Reviewed Original ResearchTreatment of treatment-resistant depressionTreatment-resistant depressionMedication discontinuation ratesTranscranial magnetic stimulationElectroconvulsive therapyPsychiatric approachApproach to treatmentAdjunctive pharmacotherapyIntervention approachesAdjunctive treatmentDiscontinuation ratesMagnetic stimulationGeneralizability resultsDepressionPharmacotherapyInclusion criteriaAntipsychoticsPsychotherapyNarrative reviewKetamine/esketamineSide effectsStudy inclusion criteriaRecent FindingsRecent evidenceDisordersBuprenorphine
1994
SPECT regional cerebral blood flow alterations in naltrexone-precipitated withdrawal from buprenorphine
van Dyck C, Rosen M, Thomas H, McMahon T, Wallace E, O'Connor P, Sullivan M, Krystal J, Hoffer P, Woods S, Kosten T. SPECT regional cerebral blood flow alterations in naltrexone-precipitated withdrawal from buprenorphine. Psychiatry Research 1994, 55: 181-191. PMID: 7701033, DOI: 10.1016/0925-4927(94)90013-2.Peer-Reviewed Original ResearchConceptsRegional cerebral blood flowRegional cerebral blood flow alterationsCerebral blood flow alterationsHexamethyl propylene amine oximeOpiate-induced analgesiaBlood flow alterationsSeverity of withdrawalCerebral blood flowOpiate-dependent patientsAnterior cingulate regionsAnterior cingulate cortexSingle photon emissionPlacebo administrationAmine oximeOpiate withdrawalRCBF ratiosWithdrawal severityBlood flowCingulate cortexCingulate regionsSignificant negative correlationBuprenorphineNaltrexonePlaceboPatients
1990
Opioid antagonist challenges in buprenorphine maintained patients
Kosten T, Krystal J, Charney D, Price L, Morgan C, Kleber H. Opioid antagonist challenges in buprenorphine maintained patients. Drug And Alcohol Dependence 1990, 25: 73-78. PMID: 2323312, DOI: 10.1016/0376-8716(90)90144-4.Peer-Reviewed Original ResearchConceptsSublingual buprenorphine treatmentBlood pressure increaseDouble-blind placeboOpioid withdrawal symptomsBlind placeboIntravenous naloxoneNaltrexone challengeOral naltrexoneLast doseBlood pressureBuprenorphine treatmentPlacebo substitutionMHPG levelsWithdrawal symptomsPlacebo challengeSignificant symptomsAntagonist challengeBuprenorphinePatientsPlaceboNaloxoneSymptomsNaltrexoneDoseMonths